Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, June 2006, p. 2207-2209, Vol. 50, No. 6
0066-4804/06/$08.00+0 doi:10.1128/AAC.00022-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Antimalarial Effects of Human Immunodeficiency Virus Type 1 Protease Inhibitors Differ from Those of the Aspartic Protease Inhibitor Pepstatin
Sunil Parikh,1*
Jun Liu,2
Puran Sijwali,1
Jiri Gut,1
Daniel E. Goldberg,2 and
Philip J. Rosenthal1
Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California,1
Department of Medicine and Department of Molecular Microbiology, Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri2
Received 6 January 2006/
Returned for modification 30 January 2006/
Accepted 6 March 2006
Human immunodeficiency virus type 1 protease inhibitors (HIVPIs) and pepstatin are aspartic protease inhibitors with antimalarial activity. In contrast to pepstatin, HIVPIs were not synergistic with a cysteine protease inhibitor or more active against parasites with the cysteine protease falcipain-2 knocked out than against wild-type parasites. As with pepstatin, HIVPIs were equally active against wild-type parasites and against parasites with the food vacuole plasmepsin aspartic proteases knocked out. The antimalarial mechanism of HIVPIs differs from that of pepstatin.
* Corresponding author. Mailing address: University of California San Francisco, Box 0811, San Francisco, CA 94110. Phone: (415) 206-8687. Fax: (415) 648-8425. E-mail: sparikh{at}medsfgh.ucsf.edu.
Antimicrobial Agents and Chemotherapy, June 2006, p. 2207-2209, Vol. 50, No. 6
0066-4804/06/$08.00+0 doi:10.1128/AAC.00022-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Lek-Uthai, U., Suwanarusk, R., Ruengweerayut, R., Skinner-Adams, T. S., Nosten, F., Gardiner, D. L., Boonma, P., Piera, K. A., Andrews, K. T., MacHunter, B., McCarthy, J. S., Anstey, N. M., Price, R. N., Russell, B.
(2008). Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of Plasmodium vivax than against Those of P. falciparum. Antimicrob. Agents Chemother.
52: 2435-2441
[Abstract]
[Full Text]
-
Skinner-Adams, T. S., Andrews, K. T., Melville, L., McCarthy, J., Gardiner, D. L.
(2007). Synergistic Interactions of the Antiretroviral Protease Inhibitors Saquinavir and Ritonavir with Chloroquine and Mefloquine against Plasmodium falciparum In Vitro. Antimicrob. Agents Chemother.
51: 759-762
[Abstract]
[Full Text]
Copyright © 2006 by the American Society for Microbiology. All rights reserved.